Constellation Pharmaceuticals Inc (CNST)


Stock Price Forecast

July 14, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Constellation Pharmaceuticals Inc chart...

About the Company

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Exchange

NASDAQ/NGS (GLOBAL SELECT MARKET)

Website

www.constellationpharma.com

$M

Total Revenue

106

Employees

$2B

Market Capitalization

-11.18

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CNST News

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

5d ago, source: Business Insider

Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST-2 trial sponsor. Tafasitamab is a humanized Fc-modified CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive ...

Constellation Brands: A Hold Amid Downturns In The Wine And Spirits Category

8d ago, source:

Constellation Brands reported strong performance in its beer segment, offset by headwinds in Wine & Spirits. Read why I rate STZ stock a Hold for now.

S&P 500 Hits New Highs: Top 5 Performing Stocks Year-to-Date

9d ago, source: The UBJ on MSN

So, you’re on the hunt for a remote job. You’ve polished your resume, updated your LinkedIn profile, and perfected your ...

Rocket Lab launches a commercial radar-imaging satellite in dramatic night liftoff (video)

6d ago, source: Space.com

Rocket Lab will launch a commercial radar-imaging satellite on Tuesday morning (March 12), and you can watch the action live.

Planful Named to Constellation Research ShortList™ for Cloud-Based Planning and Performance Management Platforms for 12th Consecutive Year

12d ago, source: TMCnet

Planful Inc., the pioneer of financial performance management cloud software, today announced that the company was named to ...

Street Calls of the Week: Upgrades for MediaAlpha and Constellation Energy

on MSN ago, source:

How did the stock react? MediaAlpha traded up on the premarket headlines from $20.02 to $20.79, a gain of 4%. MediaAlpha ...

Canada’s IPO Drought Reaches a Full Year With No End in Sight

on MSN ago, source:

Canada’s biggest market for initial public offerings is marking a grim milestone of a full year without a new corporate ...

Rocket Lab launches Synspective radar imaging satellite

6d ago, source: SpaceNews

Rocket Lab launched a radar imaging satellite for Japanese company Synspective March 12, the latest in a series of launches ...

Rocket Lab Successfully Launches 45th Electron Mission, 4th for Longtime Partner Synspective

6d ago, source:

Rocket Lab USA, Inc. (Nasdaq: RKLB) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, ...

Idorsia and Viatris successfully close the transaction for the global research and development collaboration

1d ago, source: Yahoo Finance

Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VTRS), a ...

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

5d ago, source: PharmiWeb

Annual ReportMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update 13.03.2024 / 21:01 CET/CESTThe issuer is solely responsible for the content of this ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...